# QLife Holding

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/qlifeholding).

## Overview

Qlife Holding AB is a Swedish diagnostics company built around the Egoo platform for decentralized biomarker testing. Through its subsidiary Egoo Health ApS, the group develops and commercializes home-use and point-of-care tests, devices, and consumables for blood-based health monitoring.

## Products & services

• Egoo Analyzer and related test platform
• Egoo.Health test capsules and consumables
• Home-use biomarker testing for chronic disease monitoring
• Clinical validation and regulatory development services
• Sales of diagnostic devices and consumables

- **Diagnostic devices** (35%) — Analyzer hardware used to run decentralized blood tests.
- **Test capsules and consumables** (45%) — Single-use cartridges and consumables used with the Egoo system.
- **Clinical and regulatory development** (10%) — Validation work and product development supporting market approval.
- **Service and support** (10%) — Ancillary services tied to product deployment and customer use.

- Egoo Analyzer and related test platform
- Egoo.Health test capsules and consumables
- Home-use biomarker testing for chronic disease monitoring
- Clinical validation and regulatory development services
- Sales of diagnostic devices and consumables

## Customers

Qlife sells to users and partners in decentralized diagnostics, including consumers managing chronic conditions, healthcare providers, and commercial partners evaluating the platform. The company also engages with IVD, pharmaceutical, and consumer health companies that may use the technology for collaboration, distribution, or commercialization.

- **Home users with chronic conditions** (primary) — Buy Egoo tests for convenient biomarker monitoring outside traditional labs.
- **Pharmacies and retail health channels** (secondary) — Offer in-store blood testing and related consumables to drive repeat usage.
- **Healthcare providers and hospital-at-home programs** (secondary) — Use decentralized testing to support remote monitoring and care pathways.
- **Strategic industry partners** (secondary) — IVD, pharma, and consumer health companies evaluate the platform for partnerships.

- Consumers managing chronic conditions at home
- Pharmacies and retail health channels
- Healthcare providers and hospital-at-home programs
- IVD, pharma, and consumer health partners
- Clinical study and validation collaborators

## Geography

Qlife is headquartered in Göteborg, Sweden, and reports through a Swedish parent company with Danish subsidiary Egoo Health ApS. Its commercial focus has included Scandinavia and the UK, with additional activity and partner discussions referenced in China and other international markets.

- Headquartered in Göteborg, Sweden
- Operates through subsidiary Egoo Health ApS in Denmark
- Commercial focus includes Scandinavia and the UK
- Partner activity has also referenced China
- Business is tied to regulatory access in each target market

## Strategy

Qlife is focused on commercializing decentralized diagnostics through the Egoo platform, with emphasis on regulatory milestones, product validation, and partner-led market access. The company is also pursuing pharmacy-based testing and strategic partnerships to broaden distribution and support recurring use of its consumables.

- **Regulatory approval and validation** (short-term) — Clinical and regulatory clearance is required before broad commercialization.
- **Strategic partnerships** (short-term) — Partners can accelerate distribution, credibility, and market reach.
- **Pharmacy and retail channel expansion** (medium-term) — Retail testing can increase access and testing frequency.
- **Recurring consumables model** (medium-term) — Test capsules can create repeat revenue tied to platform usage.

- Commercialize the Egoo platform in decentralized diagnostics
- Use regulatory validation to unlock broader market access
- Expand through strategic partnerships and distribution deals
- Develop pharmacy-based testing as a scalable channel
- Build recurring demand through consumables and repeat testing

## Risks

Qlife’s business depends on successful clinical validation, regulatory approvals, and partner execution before products can scale commercially. As a development-stage diagnostics company, it also faces financing, dilution, manufacturing, and market-adoption risks typical of regulated medtech businesses.

- **Regulatory approval delays** [high] — Products cannot be broadly marketed until validations and approvals are obtained.
- **Financing and dilution risk** [high] — The business is capital intensive and may need additional funding to continue development.
- **Partner and commercialization risk** [medium] — Market access depends on third-party partners and channel execution.
- **Manufacturing and purchasing risk** [medium] — Diagnostic products require reliable production of devices and consumables.
- **Intellectual property and competition** [medium] — Competing diagnostics platforms and IP disputes can limit adoption and pricing power.

- Regulatory approvals may take time and can delay commercialization
- Clinical validation risk affects whether tests can be marketed broadly
- Capital needs may require future equity or debt financing
- Partner execution risk is important for distribution and scale
- Manufacturing and supply chain issues can disrupt product availability

## Accounting

Qlife recognizes revenue from sales of goods when control transfers on delivery, which makes reported revenue sensitive to shipment timing and small order volumes. The group also capitalizes development costs and tests intangible assets for impairment, so judgments about technical feasibility, useful life, and recoverability can materially affect earnings and balance-sheet values.

- **IFRS 15 revenue recognition** — Quarterly revenue can fluctuate materially on small volumes
- **Capitalized development costs** — Affects operating expenses, assets, and future amortization
- **Impairment of intangible assets** — Can create non-cash write-downs if commercialization assumptions weaken
- **Lease accounting under IFRS 16** — Changes balance-sheet presentation and operating cost profile

- Revenue is recognized on delivery of goods under IFRS 15
- Small sales base makes quarterly revenue timing volatile
- Development costs may be capitalized if criteria are met
- Capitalized intangibles are amortized and tested for impairment
- Lease accounting affects right-of-use assets and liabilities

---

*Last updated: 2026-08-11T04:04:55.406263+00:00*